# Deepa Sampath

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4486479/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 80 papers | 3,013 citations | 159585 30 h-index | 161849 54 g-index |
| 81 all docs | 81 docs citations | 81 times ranked | 5102 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59. | 7.4 | 256 |
| 2 | microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952. | 1.4 | 200 |
| 3 | Mechanisms of apoptosis induction by nucleoside analogs. Oncogene, 2003, 22, 9063-9074. | 5.9 | 189 |
| 4 | Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene, 2008, 27, 6522-6537. | 5.9 | 188 |
| 5 | Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood, 2012, 119, 1162-1172. | 1.4 | 188 |
| 6 | H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Molecular Cancer Therapeutics, 2007, 6, 1239-1248. | 4.1 | 180 |
| 7 | Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood, 2006, 107, 2517-2524. | 1.4 | 142 |
| 8 | The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discovery, 2018, 8, 1300-1315. | 9.4 | 115 |
| 9 | Effects of Nerve Growth Factor on Glutathione Peroxidase and Catalase in PC 12 Cells. Journal of Neurochemistry, 1994, 62, 2476-2479. | 3.9 | 106 |
| 10 | BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discovery, 2018, 8, 458-477. | 9.4 | 101 |
| 11 | miRNAs and their potential for use against cancer and other diseases. Future Oncology, 2007, 3, 521-537. | 2.4 | 99 |
| 12 | Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood, 2009, 113, 3744-3753. | 1.4 | 85 |
| 13 | XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIÎ± to the Nucleus. Clinical Cancer Research, 2016, 22, 6142-6152. | 7.0 | 79 |
| 14 | Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene, 2013, 32, 3119-3129. | 5.9 | 65 |
| 15 | TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 233-243. | 4.9 | 59 |
| 16 | Inhibition of Cyclin-Dependent Kinase 2 by the Chk1-Cdc25A Pathway during the S-Phase Checkpoint Activated by Fludarabine: Dysregulation by 7-Hydroxystaurosporine. Molecular Pharmacology, 2002, 62, 680-688. | 2.3 | 58 |
| 17 | HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clinical Cancer Research, 2016, 22, 3537-3549. | 7.0 | 55 |
| 18 | Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clinical Cancer Research, 2017, 23, 6215-6226. | 7.0 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia, 2010, 24, 1893-1900. | 7.2 | 50 |
| 20 | Effects of nerve growth factor on catalase and glutathione peroxidase in a hydrogen peroxide-resistant pheochromocytoma subclone. Brain Research, 1994, 634, 69-76. | 2.2 | 44 |
| 21 | Neurotrophin Regulation of Energy Homeostasis in the Central Nervous System. Developmental Neuroscience, 1994, 16, 285-290. | 2.0 | 44 |
| 22 | Regulation of antioxidant enzyme expression by NGF. Neurochemical Research, 1997, 22, 351-362. | 3.3 | 43 |
| 23 | ATM and the Mre11-Rad50-Nbs1 Complex Respond to Nucleoside Analogueâ€"Induced Stalled Replication Forks and Contribute to Drug Resistance. Cancer Research, 2008, 68, 7947-7955. | 0.9 | 41 |
| 24 | Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. Blood, 2020, 135, 2192-2195. | 1.4 | 40 |
| 25 | Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood, 2006, 108, 4187-4193. | 1.4 | 39 |
| 26 | Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Advances, 2019, 3, 242-255. | 5.2 | 38 |
| 27 | Design of new anticancer therapies targeting cell cycle checkpoint pathways. Current Opinion in Oncology, 2001, 13, 484-490. | 2.4 | 37 |
| 28 | Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. Journal of Neuro-Oncology, 2011, 105, 241-251. | 2.9 | 37 |
| 29 | A novel interaction of PAK4 with PPARÎ³ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene, 2017, 36, 5309-5320. | 5.9 | 34 |
| 30 | The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. Cancer Research, 2018, 78, 6680-6690. | 0.9 | 33 |
| 31 | Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research, 2013, 37, 1461-1467. | 0.8 | 32 |
| 32 | Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood, 2016, 128, 3101-3112. | 1.4 | 30 |
| 33 | Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death and Disease, 2011, 2, e121-e121. | 6.3 | 27 |
| 34 | The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget, 2017, 8, 25942-25954. | 1.8 | 23 |
| 35 | Nerve Growth Factor and Oxidative Stress in the Nervous System. Advances in Experimental Medicine and Biology, 1997, 429, 173-193. | 1.6 | 22 |
| 36 | EÎ¼-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. Clinical Cancer Research, 2019, 25, 6260-6273. | 7.0 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clinical Cancer Research, 2021, 27, 2352-2366. | 7.0 | 15 |
| 38 | The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Current Oncology Reports, 2007, 9, 361-367. | 4.0 | 13 |
| 39 | Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro-Oncology, 2022, 24, 229-244. | 1.2 | 13 |
| 40 | Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease. Clinical Cancer Research, 2011, 17, 4731-4741. | 7.0 | 11 |
| 41 | Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. Blood, 2021, 138, 1550-1550. | 1.4 | 11 |
| 42 | Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy. Clinical Cancer Research, 2022, 28, 1979-1990. | 7.0 | 10 |
| 43 | miRs: fine-tuning prognosis in CLL. Blood, 2009, 113, 5035-5036. | 1.4 | 9 |
| 44 | Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of Hematology and Oncology, 2021, 14, 36. | 17.0 | 9 |
| 45 | Targeting deubiquitinases in CLL. Blood, 2017, 130, 100-101. | 1.4 | 8 |
| 46 | Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. Journal of Hematology and Oncology, 2021, 14, 101. | 17.0 | 8 |
| 47 | TP53â€altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitorâ€based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012. | 4.1 | 6 |
| 48 | HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leukemia and Lymphoma, 2019, 60, 2308-2311. | 1.3 | 5 |
| 49 | Explaining Gene Expression Using Twenty-One MicroRNAs. Journal of Computational Biology, 2020, 27, 1157-1170. | 1.6 | 5 |
| 50 | Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax. Blood, 2021, 138, 679-679. | 1.4 | 5 |
| 51 | Effect of a spinal cord photolesion injury on catalase. International Journal of Developmental Neuroscience, 1995, 13, 645-654. | 1.6 | 4 |
| 52 | Response: Context-dependent actions of miR-106b in CLL. Blood, 2009, 113, 6499-6500. | 1.4 | 3 |
| 53 | Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. Blood, 2008, 112, 2987-2987. | 1.4 | 3 |
| 54 | Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine. Blood, 2013, 122, 822-822. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation. Blood, 2014, 124, 2197-2197. | 1.4 | 3 |
| 56 | MiRly regulating metabolism. Blood, 2012, 120, 2540-2541. | 1.4 | 2 |
| 57 | Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leukemia and Lymphoma, 2018, 59, 1461-1465. | 1.3 | 2 |
| 58 | Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia, 2021, 35, 1188-1192. | 7.2 | 2 |
| 59 | MicroRNA in Leukemias. , 2013, , 97-118. | | 2 |
| 60 | The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2911-2911. | 1.4 | 2 |
| 61 | Coding and noncoding: the CLL mix. Blood, 2010, 115, 3858-3859. | 1.4 | 1 |
| 62 | Assays on DNA Damage and Repair in CLL. Methods in Molecular Biology, 2019, 1881, 153-163. | 0.9 | 1 |
| 63 | Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia. Blood, 2015, 126, 1222-1222. | 1.4 | 1 |
| 64 | Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1232-1232. | 1.4 | 1 |
| 65 | HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML. Blood, 2015, 126, 3639-3639. | 1.4 | 1 |
| 66 | Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression. Blood, 2016, 128, 2705-2705. | 1.4 | 1 |
| 67 | Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2526-2526. | 1.4 | 1 |
| 68 | The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2077-2077. | 1.4 | 1 |
| 69 | Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 2626-2626. | 1.4 | 1 |
| 70 | Dialing resistance up a Notch. Leukemia and Lymphoma, 2009, 50, 158-159. | 1.3 | 0 |
| 71 | 2.53 HDAC-Mediated Silencing of miR-17 and miR-20a in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S193-S194. | 0.4 | 0 |
| 72 | Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leukemia and Lymphoma, 2012, 53, 1013-1014. | 1.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | EXTH-84. TARGETING THE SALVAGE PATHWAY OF NAD+ GENERATION IN GLIOMAS BY KPT-9274, AÂNOVEL DUAL INHIBITOR OF PAK4 AND NAMPT. Neuro-Oncology, 2017, 19, vi91-vi91. | 1.2 | 0 |
| 74 | Shielding p53 from destruction. Blood, 2018, 131, 2740-2741. | 1.4 | 0 |
| 75 | Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p. Blood, 2008, 112, 3530-3530. | 1.4 | 0 |
| 76 | Using HSP90 Inhibitors to Target DNA Repair Proteins in AML. Blood, 2018, 132, 5144-5144. | 1.4 | 0 |
| 77 | NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia. Blood, 2018, 132, 3931-3931. | 1.4 | 0 |
| 78 | Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations. Blood, 2018, 132, 1488-1488. | 1.4 | 0 |
| 79 | Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. Blood, 2021, 138, 2252-2252. | 1.4 | 0 |
| 80 | Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy. Blood, 2021, 138, 394-394. | 1.4 | 0 |